76 SKIN CARE
5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
4.5
1.5
D0
D28 2,5% AHE
Figure 12a: Preventive soothing efficacy of 2,5% AHE application for 28 days; decrease in global reactivity score of about 67% in 97% of subjects (p<0,001); (D0 – day before treatment onset, D28 2.5% AHE – day 28 of treatment with 2,5% Alpin Heilmoor Extract).
References 1 Gomes C, et al. Peloids and pelotherapy: Historical evolution, classification and glossary. Appl Clay Sci. 2013; 1;75–76:28–38.
2 Kumar V, et al. A keratin scaffold regulates epidermal barrier formation, mitochondrial lipid composition, and activity. J Cell Biol [Internet]. 2015; 7;211(5):1057–75.
3 Borg M, et al. The role of cytokines in skin aging. Climacteric. 2013;16(5):514–21.
4 Liguori I, et al. Oxidative stress, aging, and diseases. Clin Interv Aging [Internet]. 2018; 26;13:757–72.
5 Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J Off Publ Fed Am Soc Exp Biol. 2004;18(15):1791–800.
6 Shim JH. Prostaglandin E2 Induces Skin Aging via E-Prostanoid 1 in Normal Human Dermal Fibroblasts. Int J Mol Sci [Internet]. 2019; 7;20(22):5555.
7 Peiris H, et al. RCAN1 regulates mitochondrial function and increases susceptibility to oxidative stress in mammalian cells. Oxid Med Cell Longev [Internet]. 2014;2014:520316.
8 Zhang S, Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. Cell Transplant [Internet]. 2018;27(5):729–38.
9 Lohwasser C, Neureiter D, Weigle B, Kirchner T, Schuppan D. The receptor for advanced
Control ■ 2.5% AHE ■
90 80 70 60 50 40 30 20 10 0
83%
Figure 12b: Preventive Soothing Effect of 2.5% AHE; D0.
35.0 30.0 25.0 20.0 15.0 10.0 5.0 0.0
Figure 12c: Preventive Soothing Effect of 2.5% AHE; D28.
D0 ■ D28■ -33%
29.5 -28% -34% 20.4 17.1 14.7 11.3 7.4 4.0 Microcysts Global
inflammatory lesions
Papules 1.7 1.0 Pustules Global
inflammatory lesions
Figure 14a: Anti-acne efficacy of 1,5% AHE application for 28 days; statistically significant decrease in the number of microcysts, global inflammatory lesions, global non-inflammatory lesions, papules and total lesions (p<0.0001); (D0 – day before treatment onset, d28 – day 28 of treatment with 2.5%)
glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J Invest Dermatol. 2006;126(2):291–9.
10 Shen C-Y, Lu C-H, Wu C-H, Li K-J, Kuo Y-M, Hsieh S-C, Yu C-L. The Development of Maillard Reaction, and Advanced Glycation End Product (AGE)-Receptor for AGE (RAGE) Signaling Inhibitors as Novel Therapeutic Strategies for Patients with AGERelated Diseases [Internet]. 2020 Nov 27;25(23): 5591.
11 Li L, Hartley R, Reiss B, Sun Y, Pu J, Wu D, et al. E-cadherin plays an essential role in collective directional migration of large epithelial sheets. Cell Mol Life Sci; 2012;69(16):2779–89.
12 Shin J-W, Kwon S-H, Choi J-Y, Na J-I, Huh C-H, Choi H-R, et al. Molecular Mechanisms of Dermal Aging and Antiaging Approaches. Int J Mol Sci. 2019;20(9).
13 Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31 Suppl 5:8–12.
Total lesions -46% -42% -44% 9.0 5.0 19.7
50%
48% 30%
30 sec
3 min
Figure 13: Immediate soothing effect induced by 2,5% AHE; statistically significant decrease in the mean of intensity of stinging score after 30sec (p<0,001) and 3min (p<0,001) in 55% and 70% of subjects, respectively.
PERSONAL CARE April 2021
Figure 14b: Anti-Acne efficacy of 1.5% AHE; D0.
Figure 14c: Anti-Acne efficacy of 1.5% AHE; D28.
www.personalcaremagazine.com
% of stinging intensity in mean
Average global reactivity score
mean of lesions
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90
